Literature DB >> 34837498

Advances in gene therapy for neurogenetic diseases: a brief review.

Ying-Xuan Xie1, Wen-Qi Lv1, Yi-Kun Chen1, Shunyan Hong1, Xiang-Ping Yao1, Wan-Jin Chen1, Miao Zhao2.   

Abstract

Neurogenetic diseases are neurological conditions with a genetic cause (s). There are thousands of neurogenetic diseases, and most of them are incurable. The development of bioinformatics and elucidation of the mechanism of pathogenesis have allowed the development of gene therapy approaches, which show great potential in treating neurogenetic diseases. Viral vectors delivery, antisense oligonucleotides, gene editing, RNA interference, and burgeoning viroid delivery technique are promising gene therapy strategies, and commendable therapeutic effects in the treatment of neurogenetic diseases have been achieved (Fig. 1). This review highlights a sampling of advances in gene therapies for neurogenetic disorders. Fig. 1 Examples of gene therapy strategies used in the treatment of neurogenetic diseases. The schematic diagram shows different gene therapy approaches used for treating a sampling of neurogenetic disorders, such as ASO therapy, gene editing, gene augmentation, and RNA interference.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antisense oligonucleotides (ASOs); Gene editing; Gene therapy; Neurogenetic diseases

Mesh:

Substances:

Year:  2021        PMID: 34837498     DOI: 10.1007/s00109-021-02167-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  69 in total

1.  Properties of cloned and expressed human RNase H1.

Authors:  H Wu; W F Lima; S T Crooke
Journal:  J Biol Chem       Date:  1999-10-01       Impact factor: 5.157

Review 2.  Safety of antisense oligonucleotide and siRNA-based therapeutics.

Authors:  Xuan Chi; Philip Gatti; Thomas Papoian
Journal:  Drug Discov Today       Date:  2017-01-31       Impact factor: 7.851

3.  Gene therapy for spinal muscular atrophy: hope and caution.

Authors:  Nathalie Goemans
Journal:  Lancet Neurol       Date:  2021-03-17       Impact factor: 44.182

4.  Spinal muscular atrophy: a timely review.

Authors:  Stephen J Kolb; John T Kissel
Journal:  Arch Neurol       Date:  2011-04-11

5.  Nusinersen for SMA: expanded access programme.

Authors:  Michelle A Farrar; Hooi Ling Teoh; Kate A Carey; Anita Cairns; Robin Forbes; Karen Herbert; Sandra Holland; Kristi J Jones; Manoj P Menezes; Margot Morrison; Kate Munro; Daniella Villano; Richard Webster; Ian R Woodcock; Eppie M Yiu; Hugo Sampaio; Monique M Ryan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2018-03-16       Impact factor: 10.154

Review 6.  RNA-Targeted Therapeutics.

Authors:  Stanley T Crooke; Joseph L Witztum; C Frank Bennett; Brenda F Baker
Journal:  Cell Metab       Date:  2018-04-03       Impact factor: 27.287

Review 7.  Therapeutic Antisense Oligonucleotides Are Coming of Age.

Authors:  C Frank Bennett
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

8.  Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodysplastic syndrome: initial results of a phase I trial.

Authors:  E Bayever; P L Iversen; M R Bishop; J G Sharp; H K Tewary; M A Arneson; S J Pirruccello; R W Ruddon; A Kessinger; G Zon
Journal:  Antisense Res Dev       Date:  1993

Review 9.  Antisense Drugs Make Sense for Neurological Diseases.

Authors:  C Frank Bennett; Holly B Kordasiewicz; Don W Cleveland
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-10-09       Impact factor: 13.820

Review 10.  Eteplirsen in the treatment of Duchenne muscular dystrophy.

Authors:  Kenji Rowel Q Lim; Rika Maruyama; Toshifumi Yokota
Journal:  Drug Des Devel Ther       Date:  2017-02-28       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.